What Is ChondroFiller and How Does It Work?
If you have joint wear and are weighing up non-surgical options, ChondroFiller may be worth understanding in detail. It is a CE-marked Class III medical device — a type I collagen hydrogel scaffold — administered as an ultrasound-guided outpatient injection, typically taking 30 to 60 minutes depending on the joint. There is no operation, no theatre, and no general anaesthetic.
Once injected, the collagen solution self-gels within approximately three to five minutes, filling the contours of the worn or defective area. The resulting scaffold is acellular — it contains no donor cells — and instead acts as a chemotactic matrix, attracting the patient's own progenitor cells from the surrounding synovium and subchondral bone. Those recruited cells can migrate into the scaffold, proliferate, and over time differentiate towards cartilage-producing chondrocytes. The scaffold is gradually resorbed over one to two years as new tissue forms in its place.
ChondroFiller is best understood as a supportive, joint-preserving injection. It is not a guaranteed repair, cure, or reversal of arthritis, and it is distinct from Liquid Cartilage — which is Professor Paul Y. F. Lee's keyhole surgical protocol combining the ChondroFiller scaffold with biological adjuncts and, where indicated, the patient's own stem cells. The injection pathway described here is the non-surgical route, suited to accessible lesions and patients who want to avoid theatre.
Is a Single Injection Enough? Examining the Evidence
Evidence for ChondroFiller as a device accumulates across several joints. In published series examining knee cartilage defects, International Knee Documentation Committee (IKDC) scores have improved by approximately 30 points over twelve to thirty-six months following treatment. In the hip, modified Harris Hip Scores (mHHS) have improved by over 30 points. Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores of around 80 and above have been reported, indicating substantial defect fill and tissue quality on imaging. The device has a strong safety record; across more than 19,490 units supplied since 2013, no serious incidents have been reported.
For smaller joints, a 2023 study examining an acellular collagen matrix injection for thumb-base (trapeziometacarpal) osteoarthritis reported improvements in pain and grip strength, with continued benefit at six months (Corain, M., Zanotti, F., Giardini, M., et al. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage, 2023).
Responses vary between individuals and joints, and benefits cannot be guaranteed. The evidence base is still developing, and figures from published series should not be taken as individually predictable outcomes.
Who Might Benefit Most?
ChondroFiller injection may suit people with osteoarthritis or focal cartilage wear, particularly those in earlier stages who want a non-surgical option and a relatively prompt return to activity. Clinicians value its practical profile: a single-session, reproducible injection without cell harvesting. It is suited to accessible lesions — including knee, ankle, hip, and small joints — where ultrasound guidance can reliably deliver the scaffold.
Suitability is individual. Lesion size, location, joint mechanics, overall health, and patient expectations all inform the decision. Anyone considering the injection should receive a thorough clinical assessment before proceeding.
Next Steps
ChondroFiller is a one-step, non-surgical injection that may help support a worn joint and ease symptoms for some people, without cell harvesting or theatre. It is not a cure, and realistic expectations are essential. At the London Cartilage Clinic, individual assessment determines whether the ChondroFiller injection is appropriate or whether a different pathway — including the Liquid Cartilage surgical protocol for larger or more complex defects — would better serve the patient's needs. Anyone considering treatment should consult a qualified specialist.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- ChondroFiller is a CE-marked Class III collagen hydrogel scaffold rather than a lubricant or anti-inflammatory. It self-gels in the joint to provide a three-dimensional matrix that recruits the body's own progenitor cells, aiming to support tissue regeneration over time. It requires no cell harvesting and is delivered as a single-session ultrasound-guided injection.
- People with osteoarthritis or focal cartilage wear, often in earlier stages, who want a non-surgical option with a relatively prompt recovery. Suitability depends on lesion size, location, joint condition, and individual health factors — a clinical assessment is needed to judge each case.
- The ChondroFiller injection is non-surgical: an ultrasound-guided outpatient procedure with no theatre or anaesthetic, suited to accessible lesions. Liquid Cartilage is Professor Paul Y. F. Lee's keyhole surgical protocol, which delivers the ChondroFiller scaffold arthroscopically together with biological adjuncts such as platelet-rich fibrin or plasma and, where indicated, the patient's own stem cells. They are two distinct pathways for different clinical situations.
- No. It is administered as a single injection, but individual responses vary and outcomes cannot be guaranteed. It is not a cure for arthritis, and realistic expectations are central to any informed decision about treatment.
- For larger, deeper, or load-bearing defects — particularly in the knee, hip, or shoulder — a surgical approach such as the Liquid Cartilage protocol may offer more durable repair. A thorough assessment considers lesion characteristics, joint biomechanics, and patient factors before recommending any pathway.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
